Stifel Reiterates Hold Rating on Fate Therapeutics (FATE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
TD Cowen Reiterates Hold Rating on Fate Therapeutics (FATE)
November 18, 2024 11:22 AM ESTTD Cowen analyst Tara Bancroft reiterated a Hold rating on Fate Therapeutics (NASDAQ: FATE).
The analyst commented, "The first SLE patient treated with FT819 (iCAR-T) is now past 6 months with ongoing clinical remission, low disease activity, and resolution of key quality of life... More
Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study
November 18, 2024 8:05 AM ESTFate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented initial clinical and translational data from the first patient treated in its FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American College of Rheumatology (ACR) Convergence being held in Washington, D.C. The patient, a 27-year-old African American-Asian woman diagnosed with lupus nephritis (LN) over ten years ago, received fludarabine-free conditioning followed by a single dose of... More
